Revolutionizing Pain Management
So Humanity Can Thrive
Sen-Jam Pharmaceutical is focused on improving clinical outcomes for patients battling opioid use disorder, viral respiratory infections from coronaviruses such as COVD-19 and other painful inflammation and toxin-induced conditions, including arthritis, vaccinations, and even the infamous hangover. Using our patented proprietary technology and the accelerated 505(b)2 pathway, we are on a mission to revolutionize the way we treat pain, and the way the business of pain relief treats humanity.
Repurposing
Two Small Molecules
By taking two already proven to be both effective and safe molecular agents and ingenuously combining them, Sen-Jam has discovered a simple yet powerful product that very well may change the way the world views pain relief. Our patent portfolio is rich with global relevancy and our clinical studies, both executed and planned exhibit a modern ingenuity not common to our peers.
Reimagining
Partnerships
Our strategic partnerships run the full developmental spectrum and offer a refreshingly open model for partnerships to thrive and communities to benefit in multiple ways. From licensing to distribution and beyond, we embrace an entrepreneurial can-do spirit to transform the way healthcare connects commerce to caring.
Sen-Jam’s Head of Clinical Development speaking to hundreds of innovators and health transformers at the StartUp Health Festival during JP Morgan’s Health Conference in San Francisco, January 2019
Putting an End to
The Opioid Crisis
Opioid Use Disorder is a problematic pattern of opioid use that leads to serious impairment or distress. It includes the use of prescription opoiods, heroin, or a combination of both. The intensity of withdrawal symptoms presents a significant barrier to abstinence and opioid dose reduction. Signs of chemical dependency are present within 5 days of opioid use.
SECONDS
MINUTES
overdoses
over 30K
deaths
annually
A tragedy that has killed more people annually than the AIDS crisis, Vietnam and automobile accidents combined.
It’s Time to Address This Head-on
Therapeutic Pipeline
Prescription Strength Relief
Over the Counter Relief
Over the Counter
Prescription Strength